Drug Profile


Alternative Names: PF-05082566; PF-2566; PF-5082566

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer M. D. Anderson Cancer Center; Pfizer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD137 antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I B cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 28 Sep 2017 M.D. Anderson Cancer Center and Pfizer plan a phase I trial for Colorectal cancer (Late-stage disease, Metastatic disease, In children, In adolescents, In adults, Combination therapy) in USA (NCT03290937)
  • 24 Aug 2017 MD Anderson Cancer Center, ISA Pharmaceuticals and Pfizer plans a phase II trial for Oropharyngeal cancer (Combination therapy, Monotherapy, Treatment naive, Second-line therapy or greater) in USA (SC) (NCT03258008)
  • 02 Aug 2017 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT03217747)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top